All In Biotech

Drug Trial Radar · NCT06797999

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Jun 5, 2025

Primary completion

Feb 27, 2029

Study completion Feb 27, 2029

Sponsor

Lead sponsor
Adcendo ApSIndustry
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

Conditions

  • Metastatic Soft Tissue Sarcoma
  • Unresectable Soft Tissue Sarcoma

Interventions

  • Antibody-drug conjugate (ADC)Biological

    ADCE-D01 is an antibody-drug conjugate (ADC) composed of an anti-urokinase plasminogen activator receptor-associated protein (uPARAP) antibody, AB-004, conjugated to a topoisomerase I inhibitor, P1021, via a protease cleavage tetra-peptide linker.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the MTD/maximum administered dose and RP2DS of ADCE-D01.Time frame: From enrollment to the end of Phase 1b (Approximately 18 months after enrollment)
  2. Assess the safety and tolerability of ADCE-D01Time frame: Throughout the trial duration, completion expected approximately 18 months from completed enrollment

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Colorado Denver

    Aurora, Colorado · Recruiting

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University Of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg

    Leuven, Belgium · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Institut Gustave Roussy

    Paris, Ville Juif Cedex, France · Not yet recruiting

  • Universitätsklinikum Essen West German Tumor Center

    Essen, Germany · Recruiting

  • Royal Marsden

    London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.